EGFR and non-small cell lung carcinoma: The real-world data from Taiwan presented a median OS from first-line EGFR-TKI treatment of 57.0 to 61.3 months in advanced EGFR-positive NSCLC patients with acquired T790M mutation after progressive disease under first- and second-generation EGFR-TKIs with sequential osimertinib treatment [14,20].